AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of Bristol-Myers Squibb on 8/15 was $541.96 Million, Ranking 195
ByAinvest
Friday, Aug 15, 2025 6:00 pm ET1min read
The turnover of Bristol-Myers Squibb on 8/15/2025 was $541.96 million, ranking 195 in today's market, the Volume is 11.21 million.
Bristol-Myers Squibb(BMY) shares closed at $48.44, up 1.32% on 8/15/2025, up 5.42% in the last 5 trading days, up 11.84% this month, down 14.36% year-to-date and down 1.86% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 8/15/2025 | $541.96 million | 11.21 million | $48.44 | 1.32% |
| 8/14/2025 | $448.20 million | 9.41 million | $47.81 | -0.08% |
| 8/13/2025 | $480.76 million | 10.11 million | $47.85 | 2.79% |
| 8/12/2025 | $478.33 million | 10.29 million | $46.55 | 1.35% |
| 8/11/2025 | $397.94 million | 8.66 million | $45.93 | -0.04% |
【Company Profile】
Bristol-Myers Squibb Company was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, the company changed its name to Bristol-Myers Squibb Company as a result of a merger. The company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The company expect that acquisitions of Celgene and MyoKardia will further position the company as a leading biopharmaceutical company, expanding their oncology, hematology, immunology and cardiovascular portfolios with several near-term assets and additional external partnerships.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet